| ²é¿´: 12771 | »Ø¸´: 23 | |||
³Â±ëľ³æ (СÓÐÃûÆø)
¿ÆÑй·
|
[½»Á÷]
µ°°×ÖÊ×éѧÁìÓò¡ª¡ªÈçºÎÀí½âרҵÃû´Êon-target and off-target£¿ ÒÑÓÐ2È˲ÎÓë
|
||
|
Çë½Ì´óÏÀÃÇÒ»¸öÎÊÌ⣬ÏÂÃæÕâ¾ä»°ÀïÃæµÄon-targetºÍoff-targetÈçºÎ·Ò룬ÄѵÀÊÇ¡°Ç±ÔڵİбꡱµÄÒâ˼£¿×î½ü¾³£¿´µ½ÕâÁ½¸öµ¥´Ê£¬¾ÍÊDz»ÖªµÀÈçºÎ·Ò룬¶¼¼±ËÀÁË£¡Çó¸ßÈËÏàÖú£¡¸Ð¼¤Íò·Ö£¡£¡£¡ Recent efforts in kinase research thus focus on the development of large-scale, proteome-wide chemical profiling methods capable of rapid identification of potential cellular (on- and off-) targets of kinase inhibitors. |
» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©
» ²ÂÄãϲ»¶
Wnt-C59£ºPORCN°ÐÏò»¯Ñ§Ì½Õ룬WntÐźÅͨ·×è¶Ï»úÖÆÓë¿ÆÑÐÓ¦ÓÃÈ«½âÎö
ÒѾÓÐ0È˻ظ´
Fexaramine£º³¦µÀÏÞÖÆÐÔFXR»¯Ñ§Ì½Õ룬½á¹¹ÌØÕ÷ÓëÐźÅͨ·Ñо¿È«½âÎö
ÒѾÓÐ0È˻ظ´
»¯Ñ§¹¤³Ì¼°¹¤Òµ»¯Ñ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ83È˻ظ´
NVS-STG2£º°ÐÏòSTING¿çĤÓòµÄ·Ö×Ó½ºÀ༤¶¯¼Á£¬½á¹¹ÌØÕ÷Óë¹Ñ¾Û»¯»úÖÆÑо¿È«½âÎö
ÒѾÓÐ0È˻ظ´
DOTA-GPC3ëÄ£¨CAS 3066439-94-6£©£ºË«¹¦ÄÜ·Ö×Ó̽ÕëǰÌåµÄ½á¹¹ÌØÕ÷Óë±ê¼ÇÓ¦ÓýâÎö
ÒѾÓÐ0È˻ظ´
¿ÆÑÐÓà TLR7/8 Ë«¼¤¶¯¼ÁÔõôѡ£¿ÏÖ»õÓëÖÊ¿ØÒªµã
ÒѾÓÐ0È˻ظ´
SEL120-34A HCl£ºCDK8/CDK19¸ßÑ¡ÔñÐÔ¼¤Ã¸ÒÖÖÆ¼Á
ÒѾÓÐ0È˻ظ´
ÇâÑõ»¯¼Ø»î»¯²Ù×÷
ÒѾÓÐ18È˻ظ´
É¢½ð
ÒѾÓÐ68È˻ظ´
ÉúÎïÖʳ¬¼¶µçÈÝÆ÷
ÒѾÓÐ0È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
¸µÏò¶«×ÛÊö£º·Ç±àÂëRNA¡ª¡ªµ÷¿ØÉúÎïѧµÄÇ°ÑØÁìÓò
ÒѾÓÐ1È˻ظ´
¡¾×¨Ìâ¡¿µÚÈý´ú²âÐò¼¼Êõ¡ª¡ªµ¥·Ö×Ó²âÐò
ÒѾÓÐ59È˻ظ´
°©Ö¢ÉúÎïÐÅϢѧºÍϵͳÉúÎïѧµÄ»ùÒò×éÊý¾Ý¿â×ÊÔ´¡¾×ªÌû¡¿
ÒѾÓÐ5È˻ظ´
¹ú¼Òµ°°×ÖÊ¿ÆÑ§ÖÐÐÄ£¨ÉϺ££©£¨³ï£©ÕÐÆ¸ÆôÊÂ
ÒѾÓÐ3È˻ظ´
ת¼×éÑо¿Ç°ÑØ
ÒѾÓÐ21È˻ظ´
¡¾ÆäËû¡¿Ò»ÖÖ²¡¶¾¼äÏ໥¼ä×÷ÓõÄϵͳ·ÖÀà·½·¨
ÒѾÓÐ1È˻ظ´
¸¶Ö®ÎÄ
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 22 (СѧÉú)
- ½ð±Ò: 3592.4
- É¢½ð: 522
- ºì»¨: 10
- Ìû×Ó: 630
- ÔÚÏß: 809.1Сʱ
- ³æºÅ: 1865307
- ×¢²á: 2012-06-20
- רҵ: ¿¹Ö×ÁöÒ©ÎïÒ©Àí
¡ï ¡ï ¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
³Â±ë: ½ð±Ò+2 2017-07-11 16:59:53
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
³Â±ë: ½ð±Ò+2 2017-07-11 16:59:53
| Proteomics¼ø¶¨³öµÄËùνµÄ°Ðµã»á³öÏÖ¼ÙÑôÐÔ½á¹û£¬off-target×ÖÃæÒâ˼ÊÇÍѰУ¬Ö¸µÄÊǼ¤Ã¸ÒÖÖÆ¼ÁµÄ¼ÙÑôÐ԰еã |
17Â¥2017-03-09 11:09:17
¸¶Ö®ÎÄ
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 22 (СѧÉú)
- ½ð±Ò: 3592.4
- É¢½ð: 522
- ºì»¨: 10
- Ìû×Ó: 630
- ÔÚÏß: 809.1Сʱ
- ³æºÅ: 1865307
- ×¢²á: 2012-06-20
- רҵ: ¿¹Ö×ÁöÒ©ÎïÒ©Àí
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
³Â±ë: ½ð±Ò+6, ±§Ç¸£¬»Ø¸´µÄÓÐЩÍíÁË£¬ÎÒ´ó¸Å¶®ÁË£¬·Ç³£¸ÐлÄ㣡 2017-03-21 21:41:30
³Â±ë: ½ð±Ò+5 2017-07-11 17:00:42
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
³Â±ë: ½ð±Ò+6, ±§Ç¸£¬»Ø¸´µÄÓÐЩÍíÁË£¬ÎÒ´ó¸Å¶®ÁË£¬·Ç³£¸ÐлÄ㣡 2017-03-21 21:41:30
³Â±ë: ½ð±Ò+5 2017-07-11 17:00:42
|
1. È»¶ø£¬OrlistatµÄ¸±×÷Óã¬ÈçÆäËûһЩϸ°ûÖÐÆ«ÀëµÄ°ÐµãµÄÒÖÖÆ×÷ÓûòÕßÉúÎïÀûÓöȵIJ»¼Ñ£¬¿ÉÄÜ»áÓ°ÏìËü×÷ΪһÖÖÓÐЧµÄ¿¹Ö×ÁöÒ©ÎïµÄÓ¦Óà 2. Òò´Ë£¬Yao¿ÎÌâ×éÔËÓÃABPPµÄ·½·¨ÕÒѰOrlistatеİе㣬°üÀ¨ÒýÆð¸±×÷ÓÃµÄÆ«ÀëµÄ°Ðµã 3. 3-Deazaneplanocin AÊÇÒ»Öֹ㷺ʹÓõÄhistone¼×»ù»¯ÒÖÖÆ¼Á£¬Æä×÷ÓûúÖÆÒÔ¼°Ï¸°ûÖÐÆ«ÀëµÄ°Ðµã¶¼»¹²»Ã÷È·¡£ ×ÜÖ®£¬ÕâЩoff-targets¶¼ÊÇÃû´Ê£¬Í¨Ë×À´½²¾ÍÊÇÄÇЩ²»ÊÇÄãÏëÈÃËü¹¥»÷µÄ°Ðµã¡£È磬ÄãÏëÈÃÕâ¸öÒ©Îï×÷ÓÃÔÚNaÀë×ÓͨµÀ£¬È»¶øËü³ýÁË×÷ÓÃÔÚNaͨµÀÉÏ£¨on-target)£¬Ò²×÷ÓÃÔÚKÀë×ÓͨµÀ£¬ºóÕß¾ÍÊÇoff-targetsÁË |
» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©
21Â¥2017-03-10 15:37:24
ÇÉÃöù1993
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 97.9
- Ìû×Ó: 8
- ÔÚÏß: 8.9Сʱ
- ³æºÅ: 5359600
- ×¢²á: 2016-12-15
- רҵ: ÉúÎﻯѧ
¡ï
³Â±ë(½ð±Ò+1): лл²ÎÓë
³Â±ë(½ð±Ò+1): лл²ÎÓë
|
ÓÐÄÜÁ¦Çø±ðÊÇ·ñÔÚDZÔÚϸ°û°ÐÄ¿±ê¼¤Ã¸µÄÒÖÖÆ¼Á, on,offÐÞÊεÄÊÇpotential cellual,¶ø²»ÊǺóÃæµÄtarget,Ò»¿ªÊ¼ÌýÄãÕâô˵ҲºýÍ¿ÁË£¬À¨ºÅ²»ÊÇ×¢½âÇ°ÃæµÄÂ¸öÈË¿´·¨£¬½ö¹©²Î¿¼¡£ ·¢×ÔСľ³æAndroid¿Í»§¶Ë |
13Â¥2017-03-08 21:35:31
³Â±ë
ľ³æ (СÓÐÃûÆø)
¿ÆÑй·
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 2178.6
- É¢½ð: 82
- ºì»¨: 3
- Ìû×Ó: 253
- ÔÚÏß: 118.7Сʱ
- ³æºÅ: 2446151
- ×¢²á: 2013-05-03
- ÐÔ±ð: GG
- רҵ: ÉúÎﻯѧ
|
on-target ºÍoff-targetÔÚÎÄÏ×ÀïÃæÊÇÓÐÕâÖÖ±íÊöµÄ£¬±ÈÈç˵Õâ¾ä»°Results herein thus provide important information for studying potential cellular off-targets of staurosporine in future. ÔÙ±ÈÈç˵Õâ¾ä»°In many cases, drugs have multiple protein targets, and identification of the complete target spectrum of a drug provides the most valuable information on the so-called ¡°off-targets¡± of the drug, which are unexpected protein targets that may lead to unwanted biological alterations and toxicity. ËùÒÔÄãÕâ¸ö½âÊÍÒ²ÓÐЩǷÍ× |
14Â¥2017-03-08 22:07:07
2Â¥2017-03-08 20:28:05
3Â¥2017-03-08 20:28:32
¡ï
³Â±ë(½ð±Ò+1): лл²ÎÓë
³Â±ë(½ð±Ò+1): лл²ÎÓë
|
4Â¥2017-03-08 21:06:22
¡ï
³Â±ë(½ð±Ò+1): лл²ÎÓë
³Â±ë(½ð±Ò+1): лл²ÎÓë
|
5Â¥2017-03-08 21:06:29
¡ï
³Â±ë(½ð±Ò+1): лл²ÎÓë
³Â±ë(½ð±Ò+1): лл²ÎÓë
|
6Â¥2017-03-08 21:07:59
³Â±ë
ľ³æ (СÓÐÃûÆø)
¿ÆÑй·
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 2178.6
- É¢½ð: 82
- ºì»¨: 3
- Ìû×Ó: 253
- ÔÚÏß: 118.7Сʱ
- ³æºÅ: 2446151
- ×¢²á: 2013-05-03
- ÐÔ±ð: GG
- רҵ: ÉúÎﻯѧ
7Â¥2017-03-08 21:10:41
³Â±ë
ľ³æ (СÓÐÃûÆø)
¿ÆÑй·
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 2178.6
- É¢½ð: 82
- ºì»¨: 3
- Ìû×Ó: 253
- ÔÚÏß: 118.7Сʱ
- ³æºÅ: 2446151
- ×¢²á: 2013-05-03
- ÐÔ±ð: GG
- רҵ: ÉúÎﻯѧ
8Â¥2017-03-08 21:10:47
³Â±ë
ľ³æ (СÓÐÃûÆø)
¿ÆÑй·
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 2178.6
- É¢½ð: 82
- ºì»¨: 3
- Ìû×Ó: 253
- ÔÚÏß: 118.7Сʱ
- ³æºÅ: 2446151
- ×¢²á: 2013-05-03
- ÐÔ±ð: GG
- רҵ: ÉúÎﻯѧ
9Â¥2017-03-08 21:10:55
¡ï
³Â±ë(½ð±Ò+1): лл²ÎÓë
³Â±ë(½ð±Ò+1): лл²ÎÓë
|
10Â¥2017-03-08 21:17:40









»Ø¸´´ËÂ¥
IfKplp
20